PROK1 and metformin use at conception, during pregnancy, and both at conception and during pregnancy
PCOS
s-PROK1 was lower in women who used metformin at conception (median=6.86, 95% CI 6.86 to 11.22) compared with those who did not (median=19.53, 95% CI 7.00 to 30.83) (p=0.012), regardless of later randomisation to metformin or placebo ((A) Serum levels of PROK1 at pregnancy week 19 in women with PCOS, who took metformin at conception (n=83) compared with those, who did not use metformin at conception (n=181). Values are presented as median, interquartile ranges (P25–P75) and non-outlier ranges (min-max). Open circles represent outliers (1.5*the box-height from the box). (B) Serum levels of PROK1 at pregnancy week 19 in women with PCOS, who took metformin (n=128) compared with those, who took placebo after randomisation (n=136). Values are presented as median, interquartile ranges (P25–P75) and non-outlier ranges (min-max). Open circles represent outliers (1.5*the box-height from the box).Serum levels of PROK1 at pregnancy week 19 in women with PCOS, who did not use metformin/used metformin at conception in the placebo group (n=41 and n=95, respectively) and in the metformin group (n=42 and n=86, respectively). Values are presented as median, interquartile ranges (P25–P75) and non-outlier ranges (min-max). Open circles represent outliers (1.5*the box-height from the box) and the stars represent extremes (3*the box-height from the box).